(Q50684605)

17 March 2018

title

Effects of pioglitazone and candesartan on renal fibrosis and the intrarenal plasmin cascade in spontaneously hypercholesterolemic rats. (English)

1 reference

17 March 2018

0 references

1 reference

Fumihiro Omasu

1

1 reference

17 March 2018

Takashi Oda

2

1 reference

17 March 2018

Muneharu Yamada

3

1 reference

17 March 2018

Nobuyuki Yoshizawa

4

1 reference

17 March 2018

Kazuo Yamakami

5

1 reference

17 March 2018

Yutaka Sakurai

6

1 reference

17 March 2018

Soichiro Miura

7

1 reference

17 March 2018

publication date

1 August 2007

1 reference

17 March 2018

American Journal of Physiology - Renal Physiology

published in

1 reference

17 March 2018

volume

293

1 reference

17 March 2018

issue

4

1 reference

17 March 2018

page(s)

F1292-8

1 reference

17 March 2018

The renin-angiotensin-aldosterone system and fibrinolysis in progressive renal disease

cites work

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00232.2007

Plasminogen activator inhibitor-1 and the kidney

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00232.2007

Plasminogen activator inhibitor-1 in chronic kidney disease: evidence and mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00232.2007

Plasmin is not protective in experimental renal interstitial fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00232.2007

Antifibrotic, nephroprotective potential of ACE inhibitor vs AT1 antagonist in a murine model of renal fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00232.2007

Inhibition of plasminogen activator inhibitor-1 by angiotensin II receptor blockers on cyclosporine-treated renal allograft recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00232.2007

Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00232.2007

Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00232.2007

The effect of angiotensin-converting-enzyme inhibitors on progression of advanced polycystic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00232.2007

Angiotensin II type 1 receptor blockers reduce tissue factor activity and plasminogen activator inhibitor type-1 antigen in hypertensive patients: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00232.2007

Thiazolidinediones inhibit TNFalpha induction of PAI-1 independent of PPARgamma activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00232.2007

Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00232.2007

Peroxisome proliferator-activated receptor-gamma agonist troglitazone protects against nondiabetic glomerulosclerosis in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00232.2007

Multifunctionality of PAI-1 in fibrogenesis: evidence from obstructive nephropathy in PAI-1-overexpressing mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00232.2007

Renal protective effect of candesartan cilexetil in spontaneously hypercholesterolemic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00232.2007

Glomerular plasmin-like activity in relation to nephritis-associated plasmin receptor in acute poststreptococcal glomerulonephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00232.2007

Bradykinin decreases plasminogen activator inhibitor-1 expression and facilitates matrix degradation in the renal tubulointerstitium under angiotensin-converting enzyme blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00232.2007

Plasminogen activator inhibitor type 1 is a potential target in renal fibrogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00232.2007

AT-1 receptor blockade prevents proteinuria, renal failure, hyperlipidemia, and glomerulosclerosis in the Imai rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00232.2007

Diverse effects of increasing lisinopril doses on lipid abnormalities in chronic nephropathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00232.2007

Efficacy of losartan in patients with primary focal segmental glomerulosclerosis resistant to immunosuppressive treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00232.2007

Why is proteinuria an ominous biomarker of progressive kidney disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00232.2007

Transcriptional Regulation of Nephrin Gene by Peroxisome Proliferator-Activated Receptor- Agonist: Molecular Mechanism of the Antiproteinuric Effect of Pioglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00232.2007

PAI-1 deficiency attenuates the fibrogenic response to ureteral obstruction

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00232.2007

10.1152/AJPRENAL.00232.2007

21 January 2018

Identifiers

DOI

1 reference

17 March 2018

1 reference

17 March 2018